clinical_leadership

Clinical Leadership

Stuart L. Goldstein, MD, FAAP, FASN, FNKF – Director of Clinical Development

Stuart L. Goldstein, MD, FAAP, FASN, FNKF Professor of Medicine Cincinnati Children’s Medical Center – MediBeacon Director of Clinical Development

Stuart L. Goldstein, MD, is Clark D. West Endowed Chair, Professor of Pediatrics, and the Director of the Center for Acute Care Nephrology (CACN) at Cincinnati’s Children’s Hospital Medical Center. The CACN’s mission is to serve as a nexus for all clinical, translational and outcomes research for children with, or at-risk for acute kidney injury (AKI).

Dr. Goldstein has a strong record of interdisciplinary and inter-institutional collaboration with cardiologists, intensivists and emergency center physicians. He developed and validated the pediatric modified RIFLE (pRIFLE) AKI criteria and was the Principal Investigator on the multi-national Assessment of Worldwide AKI, Renal angina and Epidemiology (AWARE) study. He was one of two pediatric work group members for the KDIGO International AKI Guideline Work Group and has served on the KDOQI Hemodialysis Adequacy, Vascular Access and Pediatric Nutrition Guideline Work Groups.

Dr. Goldstein established the Prospective Pediatric AKI Research Group (ppAKI-RG) consortium to focus on multi-centered research studies that are dedicated to understanding and treating AKI in pediatric patients. The ppAKI-RG is comprised of 52 centers from around the world with the goal of improving outcomes for the child with or at-risk for AKI.  

Dr. Goldstein is also a recognized educator; he has developed the only pediatric specific acute care nephrology sub-specialty fellowship with graduates who are now leaders in the field of pediatric AKI. He has written over 170 journal articles and is a Co-Editor of the textbook, Pediatric Nephrology. He has contributed book chapters to numerous texts including, Critical Care Nephrology, Evidence-Based Nephrology, Handbook of Dialysis Therapy, Management of Acute Kidney Problems, Pediatric Critical Care, and Pediatric Nephrology in the ICU.

Dr. Goldstein received his MD from Columbia College of Physicians and Surgeons in New York City. He completed his residency at Baylor College of Medicine in Houston Texas. He completed a fellowship in Pediatric Nephrology at The Children’s Hospital in Boston Massachusetts.

Clinical Advisory Board

Joseph V. Bonventre, MD, PhD, FASN - Professor of Medicine Harvard Medical School

Joseph V. Bonventre, MD, PhD, FASN Professor of Medicine Harvard Medical School

Dr. Bonventre is Samuel A. Levine Professor of Medicine Harvard Medical School. He is also Chief of the Renal Division of the Brigham and Women’s Hospital (BWH), Chief of the BioMedical Engineering Division at the BWH, and former Associate Director and then Co-Director of the Harvard-MIT Division of Health Sciences and Technology. Dr. Bonventre is Past-President of the American Society of Nephrology.

Dr. Bonventre received his BS with distinction from Cornell in 1970 in Engineering Physics and MD and Ph.D. degrees in Biophysics from Harvard University in 1976 and 1979, respectively. He has honorary doctorate degrees from Mt. Saint Mary’s College and from the Norwegian Institute of Science and Technology in Norway.

His research focuses primarily on the study of kidney injury and repair, with special emphasis on the role of biomarkers, inflammation and stem cells. Dr. Bonventre has received two MERIT awards from the National Institutes of Diabetes and Digestive Disorders. He has been elected to the American Society of Clinical Investigation, the Association of American Physicians and the American Institute for Medical and Biological Engineering. He is editor of Seminars in Nephrology. He serves as an advisor to many academic institutions, pharmaceutical companies and biotechnology companies. He is co-founder of Patientkeeper, Inc and Pacific Biosciences Inc.

Dr. Bonventre is past-president of the Massachusetts, Rhode Island, New Hampshire and Vermont affiliate and has received that chapter’s Outstanding Physician Award. He is a founder and member of the Board of Directors of the National Space Biology Research Institute and is an Emeritus member of the Board of Advisors of the Dean, School of Engineering of Cornell University.

Joseph V. Nally, MD Director, Center for Chronic Kidney Disease, Cleveland Clinic

Joseph V. Nally, MD, Director, Center for Chronic Kidney Disease, Cleveland Clinic

Dr. Nally is the Director of the Center for Chronic Kidney Disease at the Cleveland Clinic, and Clinical Professor of Medicine, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University in Cleveland, Ohio. Dr. Nally is a board-certified nephrologist in the Department of Nephrology and Hypertension within the Glickman Urological and Kidney Institute at the Cleveland Clinic.

Dr. Nally received his MD degree from the Ohio State University College of Medicine, trained in Internal Medicine at the OSU Hospitals in Columbus, Ohio, and trained in Nephrology at the University of Pennsylvania in Philadelphia.

Dr. Nally is currently an NIH/NIDDK funded principal investigator. His current grant is entitled “Navigating the Challenges of CKD.”

He served as a member of the Renal/ESRD Steering committee of the National Quality Forum. Dr. Nally served the National Kidney Foundation on the Medical Advisory Board and as Vice Chair of Public Policy for the Kidney Disease Outcomes Quality Initiative (KDOQI) program. Dr. Nally regularly publishes and presents at nephrology meetings. His interests include chronic kidney disease, hypertension, and renovascular disease.

Richard J. Solomon, MD, FASN, FACP Director, Division of Nephrology and Hypertension, Fletcher Allen Health Care

Richard J. Solomon, MD, FASN, FACP, Director, Division of Nephrology and Hypertension, Fletcher Allen Health Care

Dr. Solomon is Patrick Professor of Medicine at the University of Vermont College of Medicine, and the Director of the Division of Nephrology and Hypertension at Fletcher Allen Health Care, in Burlington, Vermont.

Dr. Solomon received his MD degree from Yale Medical School, trained in Internal Medicine at the University of California, San Francisco, and Nephrology at Harvard Medical School.

He is interested in acute kidney injury and in particular, prevention of contrast-induced nephropathy (CIN) and has been the principle investigator for a number of important trials in CIN prevention.

Dr. Solomon is a frequent reviewer for journals in Nephrology, Cardiology, and Radiology on the subject of acute kidney injury. He is a member of a number of Data Safety and monitoring Boards for national trials. Dr. Solomon is a member of the NIH consortium for biomarkers of kidney injury.